What is "suparnostic"

suPARnostic is a simplified double monoclonal antibody sandwich enzyme-linked immunosorbent assay ( ELISA) that measures the amount of soluble urokinase plasminogen activator receptor ( suPAR) in blood. Elevated plasma suPAR levels have been observed in various infectious, inflammatory and autoimmune diseases. suPAR concentration positively correlates to the activation level of the immune system. suPARnostic can be used as a prognostic tool to determine the severity of a disease within a patient, but is not used as a reliable diagnostic tool, as it can detect the severity of the immune response in a patient, but does not reveal the specific disease from which the patient may be suffering. Recently, increase suPAR levels were shown to be associated with increased risk of systemic inflammatory response syndrome ( SIRS)/ sepsis, cardiovascular disease, type 2 diabetes, infectious diseases, HIV, cancer tuberculosis, malaria, bacterial and viral CNS infections, rheumatoid arthritis, multiple sclerosis and mortality in the general population.